Specific Protein Plays Key Role in the Spread of Breast Cancer

Researchers from the University of Liverpool have found an explanation for how breast cancer spreads to the lungs, which could potentially hold the key to preventing the progression of the disease.

Breast cancer remains the leading cause of cancer death in women due to metastasis (the spread of a cancer from one organ or part of the body to another) and the development of resistance to established therapies.

Macrophages are the most abundant immune cells in the breast tumour and can both inhibit and support cancer progression.

Insulin-like growth factors

Led by Dr Ainhoa Mielgo the research team, from the University's Institute of Translational Medicine, conducted a study to gain a better understanding of how breast cancer associated macrophages support breast cancer metastasis with the aim of developing more effective therapies against this disease.

They found that these macrophages express high levels of specific proteins called 'insulin-like growth factors' (IGFs) 1 and 2 and this helps metastatic breast cancer cells grow in the lungs.

IGF-1 and 2 are hormones found naturally in your blood. Their main job is to regulate the effects of growth hormone (GH) in your body. However, as shown in this study, tumours can also express these proteins to help them grow and metastasize to other organs.

Significant reduction in breast cancer metastasis

75% of breast cancer patients examined showed activation of IGF receptors which correlates with increased macrophage infiltration and tumour progression.

In patients with invasive breast cancer, activation of IGF receptors increased to 87%.

The researchers found there was a significant reduction in tumour cell growth and lung metastasis in pre-clinical breast cancer models when IGFs were blocked in combination with paclitaxel, a chemotherapeutic agent commonly used to treat some of the most aggressive types of breast cancer.

The results of this research study have been published in the Oncogene journal.

Improving treatments for invasive breast cancer

Dr Mielgo said: "Our findings provide the rationale for further developing the combination of paclitaxel with IGF blockers for the treatment of invasive breast cancer.

"A better understanding of the mechanisms underlying the metastatic spreading of breast cancer is critical to improve treatment and patient outcome."

Lucy Ireland, PhD student in Dr Mielgo's group and first author of this publication, said: "I am thrilled by our findings, as the combination therapy is more effective than the current treatment in pre-clinical models of breast cancer."



Media Contact
Simon Wood
Tel: + 44 151 794 8356
Email: simon.wood@liverpool.ac.uk

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

University of Liverpool

The University of Liverpool is a public university based in the city of Liverpool, England. Founded as a college in 1881, it gained its royal charter in 1903 with the ability to award degrees and is also known to be one of the six original "red brick" civic universities.

Q: